The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity
Phase Off-cycle Timing 4 weeks Daily Dose 0 mcg Frequency Resting period before starting a new cycle
The inhibition of somatostatin by DSIP has been found by a separate study, thus leading to the speculation that this peptide might have larger and more universal functions regarding human physiology than just primary sleep promotion, for which the direct inhibitory effects of somatostatin are more than peculiar
Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog
Monoclonal antibody (mAb): in vivo, L-carnitine was reported to ameliorate the immune response (Famularo 1993)
Salinas et al., 2018